title: Trial participation disclosure and gel use behavior in the CAPRISA 004 tenofovir gel trial.
abstract: Disclosure, or open communication, by female microbicide trial participants of their trial participation and use of an investigational HIV prevention drug to a sexual partner may affect participants' trial product usage behavior and contribute to poor adherence. With mixed results from recent microbicide clinical trials being linked to differing participant adherence, insights into the communication dynamics between trial participants and their sexual partners are particularly important. We examined the quantitative association between (1) communication of trial participation to a partner and participant adherence to gel and (2) communication of trial participation to a partner and participant HIV status. An in-depth adherence and product acceptability assessment was administered to the women participating in the CAPRISA 004 trial. Additionally, we collected qualitative data related to communication of trial participation and gel use. Qualitatively, among 165 women who had reported that they had discussed trial participation with others, most (68%) stated that they communicated participation to their sexual partner. Most of the women who had communicated study participation with their partners had received a positive/neutral response from their partner. Some of these women stated that gel use was easy; only a small number said that gel use was difficult. Among women who did not communicate their study participation to their partners, difficulty with gel use was more common and some women stated that they feared communicating their participation. Quantitatively, there was no statistically significant difference in the proportions of women who had communicated study participation to a partner across different adherence levels or HIV status. A deeper knowledge of the dynamics surrounding trial participation communication to male partners will be critical to understanding the spectrum of trial product usage behavior, and ultimately to designing tailored strategies to assist trial participants with product adherence.
authors.affiliation: a Social and Behavioral Health Sciences , FHI 360, Durham , NC , USA.
authors.forename: Stacey M
authors.initials: SM
authors.lastname: Succop
authors.forename: Kathleen M
authors.initials: KM
authors.lastname: MacQueen
authors.forename: Francois
authors.initials: F
authors.lastname: van Loggerenberg
authors.forename: Nelisile
authors.initials: N
authors.lastname: Majola
authors.forename: Quarraisha Abdool
authors.initials: QA
authors.lastname: Karim
authors.forename: Salim S Abdool
authors.initials: SS
authors.lastname: Karim
mesh_terms: D000225:Adenine / Q000008:administration & dosage / Q000031:analogs & derivatives*; D000282:Administration, Intravaginal; D000328:Adult; D019380:Anti-HIV Agents / Q000008:administration & dosage*; D030881:Disclosure; D005260:Female; D005782:Gels / Q000008:administration & dosage; D015658:HIV Infections / Q000517:prevention & control*; D006801:Humans; D008297:Male; D055118:Medication Adherence / Q000523:psychology; D063065:Organophosphonates / Q000008:administration & dosage*; D010342:Patient Acceptance of Health Care; D012725:Sexual Behavior / Q000523:psychology; D012747:Sexual Partners; D000068698:Tenofovir
chemical_list: D019380:Anti-HIV Agents; D005782:Gels; D063065:Organophosphonates; D000068698:Tenofovir; D000225:Adenine
keywords: HIV prevention; adherence; covert use; disclosure; partner dynamics; vaginal microbicide